Evaluation of the Effectiveness of Remdesivir in the Treatment of COVID-19 Outpatients: A retrospective cohort study

IF 0.3 Q4 PHARMACOLOGY & PHARMACY

Current Drug Therapy Pub Date : 2023-02-28 DOI:10.2174/1574885518666230228120343

A. Asghari, Seyed Yaser Foroughi Ghomi, A. Mohammadbeigi, A. Ahmadi, S. Ahmadpour, M. Shakeri, S. Adeli, Jamshid Vafaei Manesh, Reihane Tabaraii, R. Shajari, M. Vahedian

{"title":"Evaluation of the Effectiveness of Remdesivir in the Treatment of COVID-19 Outpatients: A retrospective cohort study","authors":"A. Asghari, Seyed Yaser Foroughi Ghomi, A. Mohammadbeigi, A. Ahmadi, S. Ahmadpour, M. Shakeri, S. Adeli, Jamshid Vafaei Manesh, Reihane Tabaraii, R. Shajari, M. Vahedian","doi":"10.2174/1574885518666230228120343","DOIUrl":null,"url":null,"abstract":"\n\nThe outbreak of acute respiratory syndrome with novel coronavirus 2019 (COVID-19) in December 2019 in Wuhan, China, caused a worldwide outbreak of the disease. To treat the disease, some drugs were identified and introduced that did not show a significant effect on the recovery of the disease. Due to the need to manage inpatient beds, this study was conducted to evaluate the effectiveness of Remdesivir in the treatment of outpatients with moderate to severe COVID-19.\n\n\n\nThe present study was a retrospective cohort with a convenience sampling method. It was conducted by referring to the records of COVID-19 patients who were referred to the respiratory clinic of Shahid Beheshti Hospital as outpatients in the period from April to August 2021.\n\n\n\nThis study was conducted on 263 COVID-19 patients with a mean age of 51.16±14.39 years from 19 and 90 years old. Data were collected through a researcher-made checklist and analyzed using SPSS 20. Kolmogorov-Smirnov test, paired t-test, and Mc Nemar's test were used to evaluate the data. The significance level was considered at the level of 0.05.\n\n\n\nFindings revealed that no clear correlation was found between hospitalization and death rate compared to other patients. In our study, the risk factors for severe COVID-19 did not affect the rate of hospitalization or death of patients.\n","PeriodicalId":11004,"journal":{"name":"Current Drug Therapy","volume":" ","pages":""},"PeriodicalIF":0.3000,"publicationDate":"2023-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Drug Therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1574885518666230228120343","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

The outbreak of acute respiratory syndrome with novel coronavirus 2019 (COVID-19) in December 2019 in Wuhan, China, caused a worldwide outbreak of the disease. To treat the disease, some drugs were identified and introduced that did not show a significant effect on the recovery of the disease. Due to the need to manage inpatient beds, this study was conducted to evaluate the effectiveness of Remdesivir in the treatment of outpatients with moderate to severe COVID-19. The present study was a retrospective cohort with a convenience sampling method. It was conducted by referring to the records of COVID-19 patients who were referred to the respiratory clinic of Shahid Beheshti Hospital as outpatients in the period from April to August 2021. This study was conducted on 263 COVID-19 patients with a mean age of 51.16±14.39 years from 19 and 90 years old. Data were collected through a researcher-made checklist and analyzed using SPSS 20. Kolmogorov-Smirnov test, paired t-test, and Mc Nemar's test were used to evaluate the data. The significance level was considered at the level of 0.05. Findings revealed that no clear correlation was found between hospitalization and death rate compared to other patients. In our study, the risk factors for severe COVID-19 did not affect the rate of hospitalization or death of patients.

查看原文本刊更多论文

瑞德西韦治疗COVID-19门诊患者疗效评价:一项回顾性队列研究

2019年12月，中国武汉爆发2019年新型冠状病毒急性呼吸综合征（新冠肺炎），导致该疾病在全球范围内爆发。为了治疗这种疾病，一些药物被发现并引入，但对疾病的康复没有显著影响。由于需要管理住院床位，本研究旨在评估Remdesivir治疗中重度COVID-19门诊患者的有效性。本研究采用方便抽样的方法进行回顾性队列研究。本研究参考了2021年4月至8月期间作为门诊患者转诊至Shahid Beheshti医院呼吸科的新冠肺炎患者的记录。本研究对263名新冠肺炎患者进行，他们的平均年龄为51.16±14.39岁，分别为19岁和90岁。数据通过研究人员制作的检查表收集，并使用SPSS 20进行分析。Kolmogorov-Smirnov检验、配对t检验和Mc-Nemar检验用于评估数据。显著性水平被认为是0.05。研究表明，与其他患者相比，住院率和死亡率之间没有明显的相关性。在我们的研究中，严重新冠肺炎的危险因素并不影响患者的住院率或死亡率。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Drug Therapy PHARMACOLOGY & PHARMACY-

CiteScore

1.30

自引率

0.00%

发文量

期刊介绍： Current Drug Therapy publishes frontier reviews of high quality on all the latest advances in drug therapy covering: new and existing drugs, therapies and medical devices. The journal is essential reading for all researchers and clinicians involved in drug therapy.